SOURCE: Cutting Edge Information

Cutting Edge Information

May 21, 2015 09:00 ET

Patient-Reported Outcomes Indicate a Drug's Potential for Future Success, According to Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwired - May 21, 2015) - Life sciences companies generally discount the value of patient-reported outcomes (PROs) in favor of quantitative clinical results. However, according to a study by business intelligence firm Cutting Edge Information, these self-reported outcomes are an important indicator of a drug's potential for future success.

Regardless of a product's clinical performance, a patient will be reluctant to comply with a regimen that is difficult to follow or that negatively impacts his or her quality of life. And, with non-adherence costing the US healthcare system up to an estimated $289 billion each year, payers are looking for PROs when comparing drugs for formulary position.

"In an era of increasing competition and rising payer demands, capturing the patient voice is crucial," said Victoria Cavicchi, research analyst at Cutting Edge Information. "Companies that incorporate patient-reported outcomes into their value propositions may find themselves better situated for reimbursement and approval discussions."

Despite having long been a part of clinical trials and new molecular entity discussions, PROs have not been used to full advantage: according to the report "Patient-Reported Outcomes: Infusing the Healthcare Consumer Voice into Clinical Development and Reimbursement," PROs were reported in 30% of approved product labels between 1997 and 2002 and in 24% of product labels between 2006 and 2010.

Cutting Edge Information's PROs report provides insights and metrics, collected through primary research, that patient-reported outcomes executives can leverage to:

  • Add PRO endpoints and measurements into clinical trials to add value to drug dossiers/payer discussions;
  • Develop and standardize in-house PRO development and implementation practices;
  • Determine best-fit PRO measurements as well as decide how many to use and how to leverage them in regulatory and reimbursement discussions;
  • Build and allocate resources to dedicated PRO teams; and
  • Understand emerging topics and trends in the PRO space, including the rise of ePRO technology and its impact on data quality.

To learn more about Cutting Edge Information's patient-reported outcomes research, please visit http://cuttingedgeinfo.com/.

Contact Information